Cabaletta Bio, Inc. (CABA)
$
1.45
-0.05 (-3.45%)
Key metrics
Financial statements
Free cash flow per share
-1.7171
Market cap
132.6 Million
Price to sales ratio
80.9674
Debt to equity
0.1395
Current ratio
4.7763
Income quality
0.7255
Average inventory
0
ROE
-0.9211
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing engineered T cell therapies for patients suffering from B cell-mediated autoimmune diseases. The company employs proprietary technology, utilizing chimeric autoantibody receptor (CAAR) T cells that are specifically engineered to selectively bind to and eliminate B cells responsible for producing disease-causing autoantibodies. Its lead product candidate, DSG3-CAART, is currently undergoing a Phase I clinical trial aimed at treating mucosal pemphigus vulgaris, an autoimmune blistering skin condition, as well as hemophilia A involving Factor VIII alloantibodies. In addition, Cabaletta Bio's pipeline includes several promising candidates: MuSK-CAART, which is in the preclinical stage for treating certain patients with myasthenia gravis; FVIII-CAART, currently in the discovery stage for a specific subset of hemophilia A patients; and DSG3/1-CAART, also in the discovery stage for treating mucocutaneous pemphigus vulgaris. The company underscores its commitment to innovative research through collaborations with renowned institutions such as the University of Pennsylvania and research agreements with The Regents of the University of California. The cost of revenue for the company is $4,813,000.00 showcasing its production and operational expenses. Furthermore, the company's stock is identified with the symbol 'CABA' in the market, and it boasts a gross profit ratio of 0.00 reflecting the efficiency of its production and sales operations. The diluted EPS stands at -$2.34 taking into account potential share dilution, while the EBITDA ratio is 0.00 highlighting the company's operational efficiency. In the current market environment, Cabaletta Bio, Inc. presents an attractive investment opportunity with its stock priced affordably at $1.69 making it suitable for budget-conscious investors. The stock also enjoys a high average trading volume of 1,845,728.00 indicating a strong level of liquidity. With a market capitalization of $132,624,540.00 the company is classified as a small-cap player within the biotechnology space. As a key player in the Biotechnology industry, Cabaletta Bio significantly contributes to the overall market landscape and belongs to the Healthcare sector, driving both innovation and growth in the field.
Is Cabaletta Bio, Inc. (CABA) a good investment?
Investing in Cabaletta Bio, Inc. (CABA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Cabaletta Bio, Inc. (CABA)'s stock forecast?
Analysts predict Cabaletta Bio, Inc. stock to fluctuate between $0.99 (low) and $5.83 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cabaletta Bio, Inc.'s market capitalization?
As of 2025-08-29, Cabaletta Bio, Inc.'s market cap is $132,624,540, based on 91,465,200 outstanding shares.
How does Cabaletta Bio, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cabaletta Bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cabaletta Bio, Inc. (CABA) stock?
To buy Cabaletta Bio, Inc. (CABA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CABA. Place an order (Market, Limit, etc.).
What is the best time to invest in Cabaletta Bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Cabaletta Bio, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.34 | Growth: 41.82%.
Where can I find Cabaletta Bio, Inc.'s investor relations reports?
Visit https://www.cabalettabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cabaletta Bio, Inc.?
You can explore historical data from here
What is the all-time high and low for Cabaletta Bio, Inc. stock?
All-time high: $26.35 (2024-02-08) | All-time low: $0.59 (2022-09-23).
What are the key trends affecting Cabaletta Bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Cabaletta Bio (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –
seekingalpha.com
Cabaletta Bio's CAR T-cell therapy shows durable efficacy in autoimmune diseases, with manageable side effects and promising early clinical data updates. The company plans a BLA submission for myositis in 2027, supported by FDA's RMAT designation and a focused clinical trial strategy. Financial risk is significant: current cash plus a new offering extends runway only modestly, likely insufficient to reach commercialization without further dilution.
globenewswire.com
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). Cabaletta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Cabaletta.
globenewswire.com
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients –
globenewswire.com
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off or tapering steroids as of the latest follow-up –
See all news
